ICML 2019 | MabCute results: extended subcutaneous R maintenance for indolent NHL

Simon Rule

Simon Rule, MD, Plymouth University, Plymouth, UK, discusses the Phase III MabCute study (NCT01461928), investigating prolonged maintenance with subcutaneous rituximab in relapsed/refractory indolent non-Hodgkin lymphoma. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

Share this video